Drug Profile
Research programme: anti-fibroproliferative small molecule therapeutics - Celgene/Galecto
Alternative Names: Cancer and fibrotic disease oral therapies - Celgene/Galecto; Fibroproliferative disease therapies - Celgene/GalectoLatest Information Update: 16 Mar 2021
Price :
$50
*
At a glance
- Originator PharmAkea Therapeutics
- Developer Celgene Corporation; PharmAkea Therapeutics
- Class Small molecules
- Mechanism of Action Protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Connective tissue disorders
Most Recent Events
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb
- 28 Jul 2018 No recent reports of development identified for research development in Cancer in USA (PO)
- 28 Jul 2018 No recent reports of development identified for research development in Connective-tissue-disorders in USA (PO)